Tarsus Pharmaceuticals sees growth with Xdemvy's $180M sales in 2024. Read this article to know what makes TARS stock a BUY for growth investors.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the ...

I. Benjamin Gaddie, OD, FAAO, summarized the best forms of treating and managing demodex blepharitis. During the Southeastern Educational Congress of Optometry (SECO) 2025 meeting held from ...

Living with skin that’s prone to rosacea isn’t easy. Trying to pin down a trigger for your redness can be exhausting: It could be stress, extreme temperatures, spicy foods, fragrance ...

As Bobby noted, we are extremely excited about Ocular Rosacea. Because like DB, it is caused by Demodex mites and can impact how we look, feel and see. It can also be quickly and simply diagnosed ...

Another possible cause of rosacea is the increased presence of a common microscopic mite called Demodex folliculorum. This mite is more abundant on the skin of people with rosacea. According to ...

XDEMVY (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular ...

INDICATIONS AND USAGEXDEMVY is indicated for the treatment of Demodex blepharitis ... TP-04 for the potential treatment of Ocular Rosacea. About TP-05TP-05 is an investigational oral systemic ...

is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the ...